Robert C. Goeltz II

2018 - Unity Biotechnology

In 2018, Robert C. Goeltz II earned a total compensation of $908K as Chief Financial Officer at Unity Biotechnology.

Compensation breakdown

Non-Equity Incentive Plan$142,325
Option Awards$392,653
Salary$373,068
Total$908,046

Goeltz received $392.7K in option awards, accounting for 43% of the total pay in 2018.

Goeltz also received $142.3K in non-equity incentive plan and $373.1K in salary.

Rankings

In 2018, Robert C. Goeltz II's compensation ranked 9,660th out of 14,244 executives tracked by ExecPay. In other words, Goeltz earned more than 32.2% of executives.

ClassificationRankingPercentile
All
9,660
out of 14,244
32nd
Division
Manufacturing
3,886
out of 5,759
33rd
Major group
Chemicals And Allied Products
1,463
out of 2,122
31st
Industry group
Drugs
1,233
out of 1,811
32nd
Industry
Pharmaceutical Preparations
948
out of 1,385
32nd
Source: SEC filing on April 24, 2020.

Goeltz's colleagues

We found three more compensation records of executives who worked with Robert C. Goeltz II at Unity Biotechnology in 2018.

2018

Nathaniel David

Unity Biotechnology

President

2018

Keith Leonard

Unity Biotechnology

Chief Executive Officer

2018

Jamie Dananberg

Unity Biotechnology

Chief Medical Officer

News

You may also like